Entropy Neurodynamics Limited · ASX:ENP
Entropy Neurodynamics — Bioshares 2026 Investor Roadshow
17 slides from Entropy Neurodynamics's conference presentation, Aug 7, 2026
Slide 1: Achieving Leadership in the Treatment of Neuropsychiatry Disorders
For personal use only Achieving Leadership in the Treatment of Neuropsychiatry Disorders Bioshares 2026 Investor Roadshow ASX : ENP August 2026 This presentation has been authorised for release by the Board of EntropyENTROPY Neurodynamics Limited NEURODYNAMICS: World- First Clinical Results in Treat
Slide 2: Disclaimers
Disclamers The information contained in this presentation (the “Presentation”) has been prepared by Tryp Therapeutics Inc. (“Tryp” or the “Company”) and contains information pertaining to the business, operations and assets of the Company. The information contained in this Presentation (a) is provid
Slide 3: Overview and Investment Thesis
Overview and Investment Thesis For personal use only A unique next-generation Large addressable markets psychedelic platform: & strong IP protection • Lead asset, TRP-8803 is a proprietary IV-infusion platform therapy that • TRP-8803 targets multiple neuropsychiatric disorders with high unmet delive
Slide 4: Corporate Overview
Corporate Overview Shareholder Overview Corporate Snapshot Shareholder register as at 3 July 2026 For personal use only A SX CO DE S H AR E S O N I S S U E DEB T ENP 1.6Bn Nil A D D I T I ON A L F U ND I N G M A RK E T C A P I T A L I S A T I O N CASH AT BANK A C C E S S I B L E T H RO UG H O P T I
Slide 5: Treatment-resistant data from previous oral psilocybin studies underpin TRP-8803
Compelling treatment-resistant data from previous oral psilocybin studies underpin confidence in TRP-8803 as a precision therapy platform FM B ED I BS For personal use only Fibromyalgia Binge Eating Disorder Irritable Bowel Syndrome Chronic Pain associated with Greater than 2 BE IBS-Symptom 4 body s
Slide 6: TRP-8803 designed to remove the barriers to therapy
TRP-8803 has been specifically designed to remove the barriers to therapy For personal use only TRP-8803 : A Precision approach in Neuropsychiatry Oral Psilocybin* IV-infused Psilocin Short treatment duration of 1-2 hours ✕ ~8-10 hours ✓ Quick onset of psychedelic ✕ 1-2 hours ✓ state (~15 minutes) P
Slide 7: Variability and inconsistency of oral psilocybin vs TRP-8803
Variability and inconsistency of oral psilocybin vs TRP-8803 For personal use only Oral Psilocybin* TRP-8803 (IV Psilocin) Note: Vertical lines represent time (mins) post-dose ENTROPY NEURODYNAMICS: Advancing Psychedelic Science for Disorders in Neuropsychiatry
Slide 8: Phase 2 TRP-8803 trial in treatment-resistant Binge-Eating Disorder
Phase 2 TRP-8803 trial in treatment-resistant Binge-Eating Disorder (BED) For personal use only OV ERV IEW K E Y E F F I C AC Y M E AS U R E S P R IM AR Y EN D P O I NT Phase 2, open-label clinical trial in collaboration with Changes in binge eating Safety and tolerability Swinburne University frequ
Slide 9: Landmark trial results validate TRP-8803 as a potential treatment
Landmark trial results validate TRP-8803 as a potential treatment 50% C LI NI C A L For personal use only R EM IS S IO N TRP-8803 delivered 50% remission in treatment-resistant BED and clinical improvement in 100% of patients 100% C LI NI C A LLY M EA NI NG F U L IM P R OV E ME NT Clinical safety an
Slide 10: Additional, highly compelling findings
Additional, highly compelling findings For personal use only Depression Quality of Life Anxiety Clinical Global Next 57% reduction 63% improvement 58% reduction in Impression Q4 CY26 Results in Depression in quality of life Anxiety (GAD-7) Clinical Global from cohort 2 (12 (PHQ-9) Impression patient
Slide 11: Strategic significance
Strategic significance For personal use only Results validate TRP-8803 Significantly de-risks the Strengthens regulatory Provides additional data via EEG as a differentiated TRP-8803 development and partnering discussions analysis identifying a mechanistic precision-controlled program and progressio
Slide 12: World-first patient basket study across eight neuropsychiatric and pain disorders
World-first 72 patient basket study across eight neuropsychiatric and pain disorders Evaluating TRP-8803 indications in parallel, rather than one indication at a time. For personal use only 72 PATIENTS 8 DISORDERS 9 COHORTS 1 PROTOCOL SELECTED FOR SHARED NEUROBIOLOGY Treatment-Resistant Depression P
Slide 13: Global pharma chasing differentiated Phase 2 assets
Global pharma chasing differentiated Phase 2 assets on minimal patient data AU GU S T 2 5 , 2 0 25 J U NE 1 3 , 20 26 J U LY 1 6 , 20 26 For personal use only AbbVie tunes in to Gilgamesh's Otsuka buys Transcend in $1.2B Lilly buys AtaiBeckley for $2.8B story, inking $1.2B deal for deal, nabbing MDM
Slide 14: Aggressive absorption of global IP rights
Aggressive absorption of global IP rights Patent applications and trade secrets based on novel methods for manufacturing, formulation, dosing and treatment of specific disease indications have been filed for all major global pharmaceutical markets For personal use only BING E EAT ING D ISO RD ER FIB
Slide 15: TRP-8803 has three major growth categories for commercialisation
TRP-8803 has three major growth categories for commercialisation For personal use only Psychiatry Pain Gastroenterology Maximum efficacy 40-60% across conditions 30-40% in non-treatment resistant 20-40% in non-treatment resistant of standard of care: population – limited long-term use population due
Slide 16: Multiple pending value catalysts
Multiple pending value catalysts HREC approval granted Q3 CY26 Q4 CY26 Ongoing For personal use only Commencement of Completion of cohort 2 dosing in cohort 2 dosing in Development of 72 Phase 2 BED trial with Phase 2 BED trial TRP-8803 biomarker Swinburne University and treatment Cohort 2 topline p
Slide 17: Contact
Jason Carroll Chief Executive Officer For personal use only jcarroll@tryptherapeutics.com Henry Jordan Six Degrees Investor Relations henry.jordan@sdir.com.au CONTACT W E B S ITE : entropyneurodynamics.com S O C I AL S : X (Twitter) @tryptherapeutic
Entropy Neurodynamics — Bioshares 2026 Investor Roadshow on 6ix